Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - Aclaris Therapeutics (ACRS) is anticipated to report a year-over-year increase in earnings despite lower revenues, which could significantly influence its stock price based on actual results compared to estimates [1][2]. Financial Performance Expectations - The consensus estimate indicates Aclaris is expected to post a quarterly loss of $0.13 per share, reflecting a year-over-year change of +13.3% [3]. - Revenues are projected to be $1.55 million, representing a decline of 44% from the same quarter last year [3]. Estimate Revisions and Predictions - Over the last 30 days, the consensus EPS estimate has been revised 1.41% higher, indicating a positive reassessment by analysts [4]. - Aclaris has an Earnings ESP of +10.00%, suggesting analysts have become more optimistic about the company's earnings prospects [12]. Historical Performance and Trends - In the last reported quarter, Aclaris was expected to incur a loss of $0.17 per share but actually reported a loss of $0.12, resulting in a positive surprise of +29.41% [13]. - Over the past four quarters, Aclaris has exceeded consensus EPS estimates three times [14]. Industry Context - Another player in the Zacks Medical - Drugs industry, Zoetis (ZTS), is expected to report earnings of $1.61 per share for the same quarter, indicating a year-over-year change of +3.2% [18]. - Zoetis's revenues are expected to reach $2.4 billion, up 1.7% from the previous year [18].